دورية أكاديمية
أعرض في EDS

Troponin T1 in tumorigenesis and immune modulation: Insights into multiple cancers and kidney renal clear cell carcinoma.

التفاصيل البيبلوغرافية
العنوان: Troponin T1 in tumorigenesis and immune modulation: Insights into multiple cancers and kidney renal clear cell carcinoma.
المؤلفون: Zhang Q; Department of Urology, Xuzhou Central Hospital, Affiliated Central Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Urology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China.; School of Life Sciences, Jiangsu Normal University, Xuzhou, Jiangsu, China., Hao L; Department of Urology, Xuzhou Central Hospital, Affiliated Central Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China., Wang F; Department of Urology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China., Yu Q; Department of Urology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China., Wu S; School of Life Sciences, Jiangsu Normal University, Xuzhou, Jiangsu, China., Han C; Department of Urology, Xuzhou Central Hospital, Affiliated Central Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; School of Life Sciences, Jiangsu Normal University, Xuzhou, Jiangsu, China.
المصدر: Journal of cellular and molecular medicine [J Cell Mol Med] 2024 Jun; Vol. 28 (11), pp. e18410.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101083777 Publication Model: Print Cited Medium: Internet ISSN: 1582-4934 (Electronic) Linking ISSN: 15821838 NLM ISO Abbreviation: J Cell Mol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford, England : Wiley-Blackwell
Original Publication: Bucharest : "Carol Davila" University Press, 2000-
مواضيع طبية MeSH: Carcinogenesis*/genetics , Carcinogenesis*/immunology , Carcinogenesis*/pathology , Carcinoma, Renal Cell*/genetics , Carcinoma, Renal Cell*/immunology , Carcinoma, Renal Cell*/pathology , Carcinoma, Renal Cell*/metabolism , Gene Expression Regulation, Neoplastic* , Kidney Neoplasms*/genetics , Kidney Neoplasms*/immunology , Kidney Neoplasms*/pathology , Kidney Neoplasms*/metabolism , Troponin T*/metabolism , Troponin T*/genetics, Humans ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cell Line, Tumor ; Cell Proliferation ; DNA Methylation ; Immunomodulation/genetics ; Mutation/genetics ; Prognosis ; Tumor Microenvironment/immunology
مستخلص: Troponin T1 (TNNT1) plays a crucial role in muscle contraction but its role in cancer, particularly in kidney renal clear cell carcinoma (KIRC), is not well-understood. This study explores the expression, clinical significance and biological functions of TNNT1 in various cancers, with an emphasis on its involvement in KIRC. We analysed TNNT1 expression in cancers using databases like TCGA and GTEx, assessing its prognostic value, mutation patterns, methylation status and functional implications. The study also examined TNNT1's effect on the tumour microenvironment and drug sensitivity in KIRC, complemented by in vitro TNNT1 knockdown experiments in KIRC cells. TNNT1 is overexpressed in several cancers and linked to adverse outcomes, showing frequent upregulation mutations and abnormal methylation. Functionally, TNNT1 connects to muscle and cancer pathways, affects immune infiltration and drug responses, and its overexpression in KIRC is associated with advanced disease and reduced survival. Knocking down TNNT1 curbed KIRC cell growth. TNNT1's aberrant expression plays a significant role in tumorigenesis and immune modulation, highlighting its value as a prognostic biomarker and a potential therapeutic target in KIRC and other cancers. Further studies are essential to understand TNNT1's oncogenic mechanisms in KIRC.
(© 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
References: R Soc Open Sci. 2020 Oct 7;7(10):200871. (PMID: 33204459)
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102. (PMID: 28407145)
Iran J Biotechnol. 2023 Jan 01;21(1):e3405. (PMID: 36811103)
Gene. 2023 May 20;865:147331. (PMID: 36871674)
Muscle Nerve. 2016 Apr;53(4):564-9. (PMID: 26296490)
Nucleic Acids Res. 2018 Jul 2;46(W1):W60-W64. (PMID: 29912392)
Nat Genet. 2013 Jun;45(6):580-5. (PMID: 23715323)
Nucleic Acids Res. 2021 Jan 8;49(D1):D1420-D1430. (PMID: 33179754)
J Gene Med. 2020 Feb;22(2):e3152. (PMID: 31830337)
Bioinformatics. 2022 Jan 3;38(2):527-529. (PMID: 34323947)
Cardiovasc Res. 2008 Nov 1;80(2):209-18. (PMID: 18635554)
J Cell Mol Med. 2024 Jun;28(11):e18410. (PMID: 38853457)
Nat Commun. 2021 Mar 25;12(1):1881. (PMID: 33767157)
Environ Toxicol. 2024 Apr;39(4):2064-2076. (PMID: 38095131)
Nucleic Acids Res. 2003 Jan 1;31(1):258-61. (PMID: 12519996)
J Nanobiotechnology. 2023 Mar 24;21(1):104. (PMID: 36964516)
Sci Transl Med. 2012 Apr 18;4(130):130ra47. (PMID: 22517884)
Cancer Discov. 2018 Mar;8(3):354-369. (PMID: 29203461)
Transl Oncol. 2023 Aug;34:101693. (PMID: 37315507)
J Biomed Sci. 2019 May 22;26(1):39. (PMID: 31118017)
Nucleic Acids Res. 2019 Jan 8;47(D1):D900-D908. (PMID: 30329142)
Science. 2018 Mar 23;359(6382):1361-1365. (PMID: 29567707)
Cell Death Dis. 2021 Jan 6;12(1):51. (PMID: 33414407)
Clin Chem. 2021 Jan 8;67(1):298-307. (PMID: 33418586)
Redox Biol. 2019 Apr;22:101149. (PMID: 30822690)
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. (PMID: 38230766)
Cold Spring Harb Perspect Med. 2020 Aug 3;10(8):. (PMID: 31615865)
Nucleic Acids Res. 2021 Jan 8;49(D1):D1083-D1093. (PMID: 33196823)
J Exp Clin Cancer Res. 2018 Nov 28;37(1):291. (PMID: 30486896)
Sci Adv. 2021 Jun 4;7(23):. (PMID: 34088677)
Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):E2116. (PMID: 25848065)
J Clin Invest. 2018 Jul 2;128(7):2877-2893. (PMID: 29863498)
Theranostics. 2018 Dec 8;8(22):6386-6399. (PMID: 30613307)
EBioMedicine. 2019 Jun;44:375-386. (PMID: 31105034)
Mol Cancer. 2022 Feb 7;21(1):37. (PMID: 35130920)
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D454-8. (PMID: 15608236)
J Endocrinol Invest. 2024 Jan;47(1):149-166. (PMID: 37477865)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
J Transl Med. 2023 Aug 16;21(1):551. (PMID: 37587450)
Gut. 1999 Jul;45(1):1-4. (PMID: 10369691)
Int J Mol Sci. 2022 May 03;23(9):. (PMID: 35563486)
معلومات مُعتمدة: KY202205 This study was funded by Suqian Sci & Tech Program; 38 Suqian15 First People's Hospital 136 Youth Talent Program
فهرسة مساهمة: Keywords: KIRC; TNNT1; prognosis; tumorigenesis; tumour microenvironment
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Troponin T)
0 (TNNT1 protein, human)
تواريخ الأحداث: Date Created: 20240610 Date Completed: 20240610 Latest Revision: 20240617
رمز التحديث: 20240617
مُعرف محوري في PubMed: PMC11163025
DOI: 10.1111/jcmm.18410
PMID: 38853457
قاعدة البيانات: MEDLINE
الوصف
تدمد:1582-4934
DOI:10.1111/jcmm.18410